New trial tests chemotherapy regimen following pancreatic cancer surgery
UC’s Ahmad leads SWOG national clinical trial
A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
The University of Cincinnati’s Syed Ahmad, MD, is the national principal investigator for the phase 2 Southwest Oncology Group (SWOG) 2104 trial.
Ahmad said he began work on this project several years ago in collaboration with Heloisa Soares, MD, PhD, of the University of Utah, through their collaboration as members of the cooperative SWOG Cancer Research Network.
The trial focuses on patients with pancreatic neuroendocrine tumors. The current standard of care for these patients is surgery only, followed by observation, but a subset of patients are at high risk for their cancer to return, Ahmad said.
“In the past, we would just watch and wait as no studies had proven beneficial to prevent recurrence," said Ahmad, University of Cincinnati Cancer Center co-director and professor of surgery in UC’s College of Medicine. “However, there was a recent study in patients with advanced cancer showing the efficacy of chemotherapy drugs capecitabine and temozolomide. So we proposed and opened this combination of drugs in patients who have had surgery but are at high risk of recurrence.”
In the trial, patients who have had pancreatic neuroendocrine tumors surgically removed will be randomized to two study arms. Select patients will either receive the two chemotherapy drugs or a placebo.
“The primary endpoint is to see if we can prevent recurrence of the cancer,” Ahmad said. If the treatment regimen proves successful, it could lead to improved survival rates for these patients, he said.
The study has just opened at UC and aims to enroll 150 patients at sites throughout the country. Ahmad said being part of the SWOG Cancer Research Network helps advance research and patient care.
“It allows us to open studies at hundreds of sites to help with trial enrollment,” he said. “It allows us to open novel studies from other institutions so that our local patients have access to cutting edge therapy.”
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Featured photo at top of Dr. Ahmad. Photo/University of Cincinnati Cancer Center.
Related Stories
President picks exceptional talent
April 28, 2021
The University of Cincinnati 2021 Presidential Leadership Medal of Excellence Awards honor six undergraduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.
Grad students earn president's highest honor
April 28, 2021
The University of Cincinnati 2021 Presidential Medal of Graduate Student Excellence Awards honor three graduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.
Local 12: 180 UC med students receive white coats, students embark on journey during pandemic
August 9, 2021
The University of Cincinnati College of Medicine welcomed 180 newly admitted first-year students during the college’s 26th annual White Coat Ceremony. The ceremony was held Friday at 10 a.m. at Cincinnati Music Hall, 1241 Elm Street. Each member of the class of 2025 were presented with a white lab coat, symbolizing entry into the medical profession. Local 12 covered the event.